TP53 and cancer: Despite the large number of candidate drugs at different stages of preclinical/clinical development, no MDM2-p53 antagonist has been approved for cancer treatment due to challenges regarding efficacy and undesired toxicity (Zanjirband and Rahgozar, 2019; Mullard, 2020).